.png)
SummaryDrug shortages are no longer an exception in European supply chains, they are a permanent operating condition. For teams sourcing, distributing or analysing medicines across more than one country, the hard part is rarely noticing that a product is short. The difficulty is answering the next three questions quickly and correctly: is it short here, what may be dispensed or imported instead, and where is that alternative actually authorised?
This article explains how shortage monitoring and substitution are organised across Europe, which official sources are authoritative for what, and how procurement, supply-chain and market-access teams stitch a fragmented picture into a working answer. It is written for pharmaceutical professionals who need to act on the data, not for a general audience.
The first thing to understand is structural: "European drug shortage data" does not exist as one register. Shortage reporting is a legal obligation at the national level, so the authoritative record sits with each national competent authority, in each country's own format, rules and language. A team covering five markets is reconciling five national registers, not querying one European source.
At the European level, the European Medicines Agency coordinates supply problems for critical medicines and maintains a public shortages catalogue, with the European Shortages Monitoring Platform (ESMP) gathering availability, supply and demand information under EMA's reinforced mandate. Per EMA, the ESMP launched with basic features in November 2024 and is being expanded in stages. But EMA's remit is coordination and a focus on critical medicines, not a complete, product-level, cross-country substitution feed. The EMA medicine shortages hub is the right starting point for the EU coordination picture, and the Heads of Medicines Agencies availability directory links out to the individual national pages. Neither is a single lookup you can query at product level for every market.
Because reporting is a national duty, the authoritative shortage record for any given market is its national competent authority. The table below maps the main DACH and Western European registers, what each one actually records, and where the substitution or import question is decided. Treat each authority's register as the source of truth for its own market, and do not assume one European list covers you.
| Country | Competent authority | What it records | Alternative / import notes |
|---|---|---|---|
| Germany | BfArM (Federal Institute for Drugs and Medical Devices) | National register of supply shortages for human medicinal products, based on marketing authorisation holder reporting | aut-idem dispensing and framework-agreement rules keyed to PZN and active ingredient; shortage situations can trigger substitution and import allowances |
| Austria | BASG / AGES | National shortage register for authorised medicinal products | Substitution and supply measures decided under Austrian rules; alternatives must be authorised on the Austrian market |
| Switzerland | Swissmedic and the federal supply office | Reporting for supply-critical human medicines outside the EU framework | Non-EU authorisation status; alternatives and imports follow Swiss rules and do not inherit EU marketability |
| France | ANSM | National shortage and supply-tension lists for medicines of major therapeutic interest | Substitution and management measures under French rules; interchangeable set differs from the German one |
| Italy | AIFA | National register of unavailable and short-supply medicines | Import authorisation and substitution follow Italian rules; alternatives must be authorised in Italy |
| Spain | AEMPS | National supply-problem listing (CISMED and related reporting) | Substitution and supply measures under Spanish rules; local authorisation required for any alternative |
| EU coordination | EMA (with HMA) | Shortages catalogue for critical medicines plus the ESMP; cross-border coordination, not a per-market lookup | Coordinates measures across member states; does not replace national registers or national substitution rules |
The pattern is consistent: the authorisation status, the interchangeable products and the substitution rules are all defined at national level. That is why a brand name that is short in one country cannot simply be mapped to "the same product" in another. The identifiers, packs and even the active-ingredient presentations differ. BfArM, for example, coordinates relief measures with companies and medical societies and participates in EU-level shortage work, but the register it publishes is still a German record under German reporting duties. The BfArM supply shortages page is the authoritative German entry point, and it makes the same point in its own scope: the detailed data is national, and cross-border relief runs through EU coordination bodies rather than a shared lookup.
Knowing that a product is short is operationally useless without the answer to "what instead". And substitution is governed nationally, not centrally. In Germany, dispensing substitution runs on aut-idem rules and the framework agreement between payers and pharmacies, keyed to the pharmaceutical central number (PZN) and the active ingredient, with shortage situations triggering specific substitution and import allowances. Other markets apply their own generic-substitution and therapeutic-alternative rules, and the set of interchangeable products differs by country because authorisation and pack availability differ.
This is why "find an alternative product" is a data problem, not a single lookup. To answer it reliably you need, per market:
In practice, dependable shortage-and-substitution monitoring is built in three layers. Separating them is the difference between a repeatable process and a scramble every time a product goes short.
The national shortage registers (BfArM, BASG, Swissmedic and peers) plus EMA's coordination view for critical medicines. This layer tells you that something is short and whether an authority has issued a supply or import measure. It is authoritative but fragmented, and it does not tell you what to use instead.
Structured product data, including active ingredient, strength, form, pack, product identifiers and authorisation status, that lets you find and qualify alternatives. In the German and DACH context, the authoritative basis for authorised German products is the IFA Article Master, complemented by the ABDA data sources, including the ABDA-Artikelstamm. The practical anchor for matching is the PZN. Without this layer, layer 1 is a list of problems with no path to a solution.
The cross-references that connect a national identifier to the wider authorisation picture, so an alternative found in one country can be checked for authorisation in another. This is where most manual processes break, because a national identifier has to be reconciled against a European view that no single register publishes.
Most organisations run layer 1 by hand and struggle at layers 2 and 3, which is exactly where the data is fragmented and where a national identifier has to be reconciled with a broader view. The teams that cope best are the ones that stop treating substitution as a lookup and start treating it as a structured query against a maintained product master.
For the German-speaking markets specifically, pharmazie.com consolidates the product-master and substitution-relevant data into a single search across more than 25 pharmaceutical databases. The daily-updated basis includes the German shortage information (Lieferengpass-Datenbank) alongside the IFA Article Master and the ABDA data sources, structured product data down to the active-ingredient level, with dossiers for 63,589 active and excipient substances, and the PZN as the matching key. The Eisbergsuche® ("iceberg search") is designed to surface not just the exact hit but the related products, alternatives and connected records behind it, which is precisely the part that manual register lookups miss.
On update cadence, the product master, shortage information and news are refreshed daily, while price data is updated bi-weekly. For buyers who need to move from availability check to order, the MSV3-Client interface (availability query and digital ordering on the purchaser side) is live and in production as a standard add-on module; the MSV3-Server interface on the seller side is currently in a pilot phase.
Two boundaries matter here, because getting them wrong is how teams get burned:
First, this is a DACH-focused structured layer. It is comprehensive for the German-speaking markets, with product data across more than 50 countries, but it is not a substitute for each national authority's own shortage register. Use the national registers as the system of record for shortage status. Second, price coverage is focused on DACH plus some additional EU countries, not on Europe as a whole, with further countries being added in the coming months.
Put plainly: keep the national registers as the source of truth for whether something is short, and use a structured product-master layer to answer the "what may I use instead, and is it authorised" question fast.
Europe does not offer a single shortage database, and it is unlikely to, because reporting obligations and substitution rules are set nationally. The workable answer is not to wish for one register but to build the workflow the fragmentation demands: national registers for the shortage fact, EMA and HMA for coordination, and a structured, identifier-anchored product data layer for the substitution and authorisation questions. For the DACH markets, that structured layer is what turns "product X is short here" into "product Y with the same active ingredient is authorised there" without five separate manual searches.
See how a structured, PZN-anchored data layer maps a shortage to authorised alternatives across the German-speaking markets. Book a demo.
About: pharmazie.com is operated by DACON Datenbank Consulting GmbH (founded 1989). It brings more than 25 pharmaceutical databases into one search for pharmaceutical professionals, with daily-updated product and shortage data for the German-speaking markets and product data across more than 50 countries. It is a professional data service and is not intended for patients.
